Eylea Injection, Solution
NDC Package 61755-005-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Eylea (aflibercept) injection is aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This formulation utilizes a injection, solution delivery system. Marketed by Regeneron Pharmaceuticals, Inc., this product is identified by NDC 61755-005 and is authorized under FDA application BLA125387.

Identification & Billing

NDC Package Code
61755-005-01
Package Description
1 SYRINGE, GLASS in 1 CARTON / .05 mL in 1 SYRINGE, GLASS
Product Code
61755-005
11-Digit Billing Format
61755000501
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Eylea
Non-Proprietary Name
Aflibercept
Substance Name
Aflibercept
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
AFLIBERCEPT 40 mg/mL
Pharmacologic Class
Usage Information
Aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

Regulatory & Marketing

Labeler Name
Regeneron Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA125387
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-21-2011
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0178
Source: PDAC
INJECTION, AFLIBERCEPT, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (61755-005). Click a package code to view its specific billing and regulatory data.

61755-005-02
1 VIAL, SINGLE-USE in 1 CARTON / .05 mL in 1 VIAL, SINGLE-USE
61755-005-54
1 SYRINGE, GLASS in 1 CARTON / .05 mL in 1 SYRINGE, GLASS
61755-005-55
1 VIAL, SINGLE-USE in 1 CARTON / .05 mL in 1 VIAL, SINGLE-USE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61755-005-01 identifies a specific commercial package of 1 syringe, glass in 1 carton / .05 ml in 1 syringe, glass of Eylea, a human prescription drug labeled by Regeneron Pharmaceuticals, Inc.. This injection, solution is formulated for intravitreal use and contains aflibercept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Regeneron Pharmaceuticals, Inc. on November 21, 2011. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

How is this Regeneron Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61755000501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61755-005-01
11-Digit CMS (5-4-2)
61755-0005-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.